Fact on Q3 reports.
New order down from 7 to 5 this Q
Burn rate the same (~20M)
Margin the same. (slightly less, ~17%).
Revenue slightly higher (~7M)
Roche deal was just a throwing in the tower deal. Still an anemic company.
Compared to ILMN, 10% jump, HiSeq new order historically high.